Should You Buy CymaBay Therapeutics Inc (CBAY) Stock on Thursday?

Thursday, November 30, 2023 12:27 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy CymaBay Therapeutics Inc (CBAY) Stock on Thursday?

The market has been high on CymaBay Therapeutics Inc (CBAY) stock recently. CBAY gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CymaBay Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CBAY!

See Full CBAY Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CBAY Stock Today?

CymaBay Therapeutics Inc (CBAY) stock is up 3.97% while the S&P 500 is down -0.25% as of 12:17 PM on Thursday, Nov 30. CBAY has risen $0.74 from the previous closing price of $18.78 on volume of 1,079,163 shares. Over the past year the S&P 500 is higher by 14.69% while CBAY has risen 495.12%. CBAY lost -$0.93 per share in the over the last 12 months. To screen for more stocks like CymaBay Therapeutics Inc click here.

More About CymaBay Therapeutics Inc

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta. Click Here to get the full Stock Report for CymaBay Therapeutics Inc stock.